Gastrointestinal tumor
Conditions
Interventions
Experimental group:immunonutrient
Control group:Common nutrient
Sponsors
Peking Union Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Gender is not limited 2. Over 18 years old, under 80 years old 3. Histologically or cytologically diagnosed patients with gastrointestinal tumors who have recently decided to undergo surgical treatment 4. Patients who, according to the investigators' judgment, need nutritional support therapy: (NRS2002 score =3 or expected to be unable to eat 60% of the recommended intake through mouth for more than 1 week 5. Liver and kidney function: ALT, AST=2.5 times the normal upper limit (with liver metastasis =5 times the normal upper limit) Serum total bilirubin (TBIL) was less than 1.5 times the normal upper limit. Serum creatinine (SCr) < 1.5 times the upper limit of normal Serum triglyceride (TG) < 1.5 times the normal upper limit 6. Those who can tolerate enteral nutrition 7. Voluntary consent and signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Can not tolerate or cannot oral/tube feeding enteral nutrition; 2. Diseases that seriously affect the digestion and absorption of test materials; Such as acute pancreatitis, gastrointestinal failure, complete intestinal obstruction, gastrointestinal active bleeding, severe diarrhea and other patients with severe digestive and absorption dysfunction; 3. Those who are using nutrition preparations containing n-3 fatty acid milk, arginine, nucleotide and glutamine; 4. Those who are using thymosin, glucocorticoids, thyroxine, growth hormone, anti-tumor necrosis factor and other drugs that may enhance the immune function of the body; 5. Patients with major organ dysfunction, multiple organ dysfunction, or severe metabolic abnormalities; 6, patients with recent non-surgical treatment; 7. Pregnant or lactating women or fertile women with positive baseline pregnancy test; 8. Allergic to sample ingredients; 9. The researcher considers that it is not suitable to participate in this research
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intestinal barrier index;Immune cell number/ratio;Immune protein content;C reactive protein; | — |
Secondary
| Measure | Time frame |
|---|---|
| Albumin/prealbumin;Physical measurement indicators (including height, weight, body fat measurement, etc.); | — |
Countries
China
Contacts
Public ContactWeiming Kang
Peking Union Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed